Oct. 7 (Bloomberg) -- GlaxoSmithKline Plc will triple its flu vaccine manufacturing capacity in North America in the next few years as concerns rise about the potential of a pandemic bird flu outbreak, Chief Executive Jean-Pierre Garnier said.
Oct. 7 (Bloomberg) -- GlaxoSmithKline Plc will triple its flu vaccine manufacturing capacity in North America in the next few years as concerns rise about the potential of a pandemic bird flu outbreak, Chief Executive Jean-Pierre Garnier said.